Select Page

Rare and Orphan Disease Conference

ABOUT THE EVENT Attendees of the 2.5-day conference, including patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists, will leave with an understanding of:  C-Path's Rare and Orphan Disease Program's current and future impact on drug development in rare diseases from the perspectives of patients, regulators and industry partners  The Critical Path for Rare […]

Rare Neurodegenerative Disease Efforts Under the ACT for ALS

Virtual or In Person

This hybrid meeting will provide an opportunity to share the 2024 priorities for Critical Path for Rare Neurodegenerative Diseases (CP-RND) program to provide an update on efforts from the Food and Drug Administration (FDA) and National Institutes of Health (NIH) focused on rare neurodegenerative diseases. Efforts within CP-RND  Update from FDA on rare neurodegenerative efforts […]